admin – Page 4273 – Get News Story

LiTime Launches Its First Plug-and-Play Lithium Golf Cart Batteries and Seeks Golf Enthusiasts for the LiTime Pro Program

LiTime, a leader in lithium iron phosphate (LiFePO4) battery technology, officially launched its first plug-and-play LiTime 48V (51.2V) 100Ah golf cart lithium battery on January 8 this year. Featuring an integrated mounting bracket, positioning plate, and a convenient top handle, the battery significantly simplifies the installation process, providing users with a hassle-free experience. Additionally, LiTime is inviting golfers and enthusiasts worldwide to join its “LiTime Pro Club” program.

275c68f739242942607858d8d0d869cf

LiTime Pro Club Recruitment Program for Golfers and Enthusiasts

To further explore the potential of lithium iron phosphate batteries in different applications and to thank its loyal customers, LiTime has launched the “LiTime Pro Club”. The program seeks enthusiasts who share LiTime’s brand values, are familiar with the company’s product features, and can effectively engage with consumers in a variety of fields.

LiTime will offer sponsorship and platform support to these Pro players, helping them achieve personal milestones and push boundaries in their careers. By partnering with LiTime, Pro players not only get the chance to showcase their talents but also open doors to even greater achievements.

If you’re passionate about golf and want to grow alongside LiTime, they invite you to join the LiTime Pro Club and contribute to the continued growth of the brand. Please reach out to LiTime via email at: collabconnect@litime.com.

LiTime 48V Lithium Golf Cart Batteries

The LiTime 48V 100Ah lithium golf cart battery features a custom-designed mounting bracket at the bottom. When replacing the old battery, users can easily position the new battery using the included positioning plate, ensuring it is securely fixed. The top handle design further simplifies handling and installation, making the replacement process straightforward and greatly improving the overall user experience. This battery also comes with the following features:

8f1ab98fa977428dbd2d8c792acc649c

Real-Time Battery Status Display: Unlike traditional golf cart batteries, which offer no way to monitor battery status, LiTime’s battery addresses this concern by offering a display that is fully compatible with the same communication protocol. Users can view critical information such as the battery’s state of charge (SOC), voltage, current, temperature, and more in real time, giving golfers peace of mind by removing any uncertainty about battery status and enhancing their overall experience.
Proprietary BMS Provides Comprehensive Safety: The LiTime 48V golf cart battery is equipped with a powerful 200A battery management system (BMS), designed specifically for high-load and high-performance applications. The system can manage current outputs of 600A (1 second), 360A (10 seconds), and 200A (120 seconds), ensuring the battery runs smoothly and safely even during intense activities like acceleration or climbing hills. The BMS also includes 20 safety protocols that prevent issues such as overcharging, overdischarging, overcurrent, overheating, low temperatures, and short circuits, ensuring long-term stability and safety in complex conditions. The battery also features an internal vent valve that helps stabilize internal pressure, providing extra safety under extreme use. The battery’s intelligent management system, operating through RS485/CAN communication protocols, enables precise monitoring and performance management, ensuring the battery’s status is always under control, offering users a safer and more reliable experience.
EV LiFePO4 Cells Provide Extended Range: All LiTime products are equipped with highly efficient EV LiFePO4 cells, which offer over 4000 charge cycles at 100% depth of discharge (DOD), ensuring a lifespan of over 10 years. With top-quality cells, the LiTime 48V golf cart battery delivers 5120Wh of energy per unit. In real-world tests, a fully charged battery can power a golf cart for about 46 miles—roughly the equivalent of 10 full rounds on a standard 18-hole golf course. This makes the battery more than capable of meeting long-use demands on the course, providing electric golf carts with steady, reliable power. For more in-depth information, please check out the article “How Long Do Golf Cart Batteries Last,” written by LiTime’s technical support team.

The LiTime 48V 100Ah lithium golf cart battery is priced at $1999.99, with a limited-time special bundle price of $1299.99 for the set (which includes the battery, 58.4V 18A charger, and display screen) during the product launch period. For additional user reviews of LiTime batteries, please visit LiTime Battery Review.

About LiTime

LiTime is a company with 16 years of experience in the new energy storage sector. Focused on user needs and powered by technological innovation, LiTime continually pushes forward in its mission to deliver the best value in lithium iron phosphate batteries. To date, LiTime’s battery technology has earned more than 380 product certifications. Guided by the brand philosophy of “Life & Discovery,” LiTime stands as an industry leader, dedicated to providing green, sustainable, and efficient energy solutions, while making a significant contribution to reducing the global carbon footprint and reshaping the power grid landscape.

Media Contact
Company Name: Shenzhen LiTime Technology Co., Ltd
Contact Person: Shafee Chang
Email: Send Email
Country: China
Website: www.litime.com

Treatment Resistant Depression Market Revenue to Expand Significantly by 2032, States DelveInsight Report | Johnson & Johnson, Novartis, COMPASS Pathways, GH Research Ireland Limited, atai Therapeutic

The Key Treatment Resistant Depression Companies in the market include – Johnson & Johnson, Novartis, COMPASS Pathways, GH Research Ireland Limited, atai Therapeutics, Inc., Beckley Psytech Limited, Navitor Pharmaceuticals, Denovo Biopharma, Perception Neuroscience, and others.

DelveInsight’s “Treatment Resistant Depression Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Treatment Resistant Depression, historical and forecasted epidemiology as well as the Treatment Resistant Depression market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Treatment Resistant Depression, offering comprehensive insights into the Treatment Resistant Depression revenue trends, prevalence, and treatment landscape. The report delves into key Treatment Resistant Depression statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Treatment Resistant Depression therapies. Additionally, we cover the landscape of Treatment Resistant Depression clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Treatment Resistant Depression treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Treatment Resistant Depression space.

To Know in detail about the Treatment Resistant Depression market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Treatment Resistant Depression Market Forecast

Some of the key facts of the Treatment Resistant Depression Market Report:

The Treatment Resistant Depression market size was valued ~USD 3,100 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
In October 2024, Denovo Biopharma LLC, a leader in utilizing precision medicine for the development of innovative drugs, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to DB104 (liafensine) for the treatment of patients with treatment-resistant depression (TRD). Fast Track designation can accelerate the review process for drugs intended to treat serious or life-threatening conditions and that show potential to meet an unmet medical need for such conditions.
In March 2024, atai Life Sciences (NASDAQ: ATAI), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders, announced today encouraging initial results from Beckley Psytech’s Phase 2a open-label study of BPL-003 in Treatment Resistant Depression (TRD), a condition impacting roughly 100 million people globally
In 2022, the United States held the largest share of the Treatment-Resistant Depression market among the 7MM, with a market size of approximately USD 2,400 million. This figure is projected to grow further by 2032.
In 2022, the UK had a market size of approximately USD 110 million, and it is projected to grow further during the forecast period.
In January 2025, The FDA approved Johnson & Johnson’s Spravato (esketamine) as the first and only standalone treatment specifically for treatment-resistant depression (TRD).
In November 2024, In Q3 2024, atai Life Sciences shared updates on its pipeline, highlighting the FDA’s approval of an Investigational New Drug (IND) application for VLS-01, a buccal film formulation of DMT. The company aims to commence a Phase 2 trial of VLS-01 for treatment-resistant depression by the end of the year. Furthermore, atai is on schedule to initiate a Phase 2 study of EMP-01 (oral R-MDMA) for social anxiety disorder by late 2024.
In October 2024, Denovo Biopharma LLC announced that the FDA has awarded Fast Track designation to DB104 (liafensine), a treatment under development for treatment-resistant depression (TRD). This designation could accelerate the review process for DB104, a therapy aimed at addressing the significant unmet need for patients unresponsive to standard antidepressant treatments.
Key Treatment Resistant Depression Companies: Johnson & Johnson, Novartis, COMPASS Pathways, GH Research Ireland Limited, atai Therapeutics, Inc., Beckley Psytech Limited, Navitor Pharmaceuticals, Denovo Biopharma, Perception Neuroscience, and others

Key Treatment Resistant Depression Therapies: SPRAVATO (esketamine), MIJ821, COMP360 (Psilocybin), GH001, VLS-01-203 BU, BPL-003, Psilocybin, NV-5138, Liafensine, Psilocybin, PCN-101, and others
The Treatment Resistant Depression market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Treatment Resistant Depression pipeline products will significantly revolutionize the Treatment Resistant Depression market dynamics
Emerging therapies for Treatment-Resistant Depression, such as Novartis’ MIJ821, COMPASS Pathways’ COMP360 (Psilocybin), Beckley Psytech’s BPL-003, Navitor Pharmaceuticals’ NV-5138, and others, hold the potential to significantly impact and drive growth in the Treatment-Resistant Depression market.
In 2022, the total diagnosed prevalent cases of Treatment-Resistant Depression in the 7MM were around 6,409,000 and are expected to rise throughout the forecast period (2023–2032.
In 2022, the United States accounted for the majority of diagnosed prevalent cases of Treatment-Resistant Depression in the 7MM, comprising approximately 71% of the total cases. In comparison, the EU4 and the UK represented around 25%, while Japan contributed approximately 4% of the diagnosed cases in the 7MM.
According to DelveInsight, approximately 512,000 cases of Treatment-Resistant Depression were reported in males and 1,117,000 cases in females across the EU4 and the UK in 2022. These numbers are expected to rise over the forecast period.
In 2022, the highest number of Treatment-Resistant Depression cases in the US was observed in individuals aged 50–60 years, while the lowest number was recorded in the 18–29-year age group.

Treatment Resistant Depression Overview

Treatment-Resistant Depression (TRD) refers to a form of major depressive disorder (MDD) that does not respond adequately to standard antidepressant treatments. Patients are typically diagnosed with TRD if their symptoms persist despite undergoing at least two different antidepressant therapies, each at an adequate dose and duration.

Get a Free sample for the Treatment Resistant Depression Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/treatment-resistant-depression-trd-market

Treatment Resistant Depression Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Treatment Resistant Depression Epidemiology Segmentation:

The Treatment Resistant Depression market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Total Prevalence of Treatment Resistant Depression
Prevalent Cases of Treatment Resistant Depression by severity
Gender-specific Prevalence of Treatment Resistant Depression
Diagnosed Cases of Episodic and Chronic Treatment Resistant Depression

Download the report to understand which factors are driving Treatment Resistant Depression epidemiology trends @ Treatment Resistant Depression Epidemiology Forecast

Treatment Resistant Depression Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Treatment Resistant Depression market or expected to get launched during the study period. The analysis covers Treatment Resistant Depression market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Treatment Resistant Depression Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Treatment Resistant Depression Therapies and Key Companies

SPRAVATO (esketamine): Johnson & Johnson
MIJ821: Novartis
COMP360 (Psilocybin): COMPASS Pathways
GH001: GH Research Ireland Limited
VLS-01-203 BU: atai Therapeutics, Inc.
BPL-003: Beckley Psytech Limited
Psilocybin: COMPASS Pathways
NV-5138: Navitor Pharmaceuticals
Liafensine: Denovo Biopharma
Psilocybin: COMPASS Pathway
PCN-101: Perception Neuroscience

Discover more about therapies set to grab major Treatment Resistant Depression market share @ Treatment Resistant Depression Treatment Landscape

Treatment Resistant Depression Market Drivers

Emerging Treatment Resistant Depression Therapies
Increased Awareness and Diagnosis
Advances in Personalized Medicine
Rising Prevalence of Depression
Improved Access to Mental Health Care
Government and Institutional Support

Treatment Resistant Depression Market Barriers

High Cost of Treatments
Limited Availability of Effective Therapies
Stigma Surrounding Mental Health
Side Effects and Safety Concerns
Regulatory Challenges
Lack of Long-term Data

Scope of the Treatment Resistant Depression Market Report

Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Treatment Resistant Depression Companies: Johnson & Johnson, Novartis, COMPASS Pathways, GH Research Ireland Limited, atai Therapeutics, Inc., Beckley Psytech Limited, Navitor Pharmaceuticals, Denovo Biopharma, Perception Neuroscience, and others
Key Treatment Resistant Depression Therapies: SPRAVATO (esketamine), MIJ821, COMP360 (Psilocybin), GH001, VLS-01-203 BU, BPL-003, Psilocybin, NV-5138, Liafensine, Psilocybin, PCN-101, and others
Treatment Resistant Depression Therapeutic Assessment: Treatment Resistant Depression current marketed and Treatment Resistant Depression emerging therapies
Treatment Resistant Depression Market Dynamics: Treatment Resistant Depression market drivers and Treatment Resistant Depression market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Treatment Resistant Depression Unmet Needs, KOL’s views, Analyst’s views, Treatment Resistant Depression Market Access and Reimbursement

To know more about Treatment Resistant Depression companies working in the treatment market, visit @ Treatment Resistant Depression Clinical Trials and Therapeutic Assessment

Table of Contents

1. Treatment Resistant Depression Market Report Introduction

2. Executive Summary for Treatment Resistant Depression

3. SWOT analysis of Treatment Resistant Depression

4. Treatment Resistant Depression Patient Share (%) Overview at a Glance

5. Treatment Resistant Depression Market Overview at a Glance

6. Treatment Resistant Depression Disease Background and Overview

7. Treatment Resistant Depression Epidemiology and Patient Population

8. Country-Specific Patient Population of Treatment Resistant Depression

9. Treatment Resistant Depression Current Treatment and Medical Practices

10. Treatment Resistant Depression Unmet Needs

11. Treatment Resistant Depression Emerging Therapies

12. Treatment Resistant Depression Market Outlook

13. Country-Wise Treatment Resistant Depression Market Analysis (2019–2032)

14. Treatment Resistant Depression Market Access and Reimbursement of Therapies

15. Treatment Resistant Depression Market Drivers

16. Treatment Resistant Depression Market Barriers

17. Treatment Resistant Depression Appendix

18. Treatment Resistant Depression Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Treatment Resistant Depression Market Revenue to Expand Significantly by 2032, States DelveInsight Report | Johnson & Johnson, Novartis, COMPASS Pathways, GH Research Ireland Limited, atai Therapeutic

Airflow Heating & Air Conditioning Offers Expert Air Conditioning Repair Services in Skokie, IL

Airflow Heating & Air Conditioning offers expert AC repair services in Skokie, IL, ensuring fast, reliable solutions with certified technicians and same-day service.

Skokie, IL – January 29, 2025 – Airflow Heating & Air Conditioning, a trusted provider of HVAC solutions, is proud to offer top-tier air conditioning repair services to homeowners and businesses in Skokie, IL, and the surrounding areas. With years of expertise in the industry, the company ensures fast, efficient, and reliable solutions to keep indoor spaces comfortable year-round.

As temperatures fluctuate, a fully functional air conditioning system is essential for maintaining a comfortable and energy-efficient environment. Airflow Heating & Air Conditioning specializes in diagnosing and repairing AC units of all makes and models, addressing issues such as insufficient cooling, strange noises, refrigerant leaks, and system breakdowns. Their team of certified technicians is committed to delivering prompt and effective services to restore optimal performance to air conditioning units.

“Customer satisfaction and comfort are our top priorities”. “We understand the urgency of AC issues, especially during extreme weather conditions. Our expert team is dedicated to providing same-day and emergency repair services to ensure that our clients’ cooling systems function efficiently.”

Why Choose Airflow Heating & Air Conditioning for AC Repairs?

Certified and Experienced Technicians – Skilled professionals with extensive knowledge of AC systems.
Fast and Reliable Service – Same-day and emergency repair options available.
Comprehensive Diagnostics – Thorough inspections to identify and resolve issues effectively.
Affordable Pricing – Transparent pricing with no hidden fees.
Customer Satisfaction Guaranteed – High-quality repairs backed by a commitment to excellence.

In addition to air conditioning repair, Airflow Heating & Air Conditioning provides a full range of HVAC services, including AC installation, maintenance, heating solutions, and indoor air quality improvements.

Residents and businesses in Skokie, IL, looking for dependable air conditioning repair services can contact Airflow Heating & Air Conditioning at:

Call us today at (877) 538-1584 to schedule your service or visit us online to explore our full range of services.

About Airflow Heating & Air Conditioning

Airflow Heating & Air Conditioning is a leading HVAC company serving Skokie, IL, and surrounding communities. Specializing in air conditioning and heating services, the company is dedicated to providing high-quality solutions that enhance comfort and energy efficiency for residential and commercial customers. With a commitment to excellence, their team ensures top-notch service and customer satisfaction.

Media Contact
Company Name: AirFLow Heating and AC
Contact Person: Yoram Danino
Email: Send Email
Phone: (877) 538-1584
Address:9052 Terminal Ave.
City: Skokie
State: IL 60077
Country: United States
Website: https://airflowac.com/

Fibrodysplasia Ossificans Progressiva Market Set to Grow Substantially Through 2032, DelveInsight Projects | Ipsen, Regeneron Pharmaceutical, Biocryst

The Key Fibrodysplasia Ossificans Progressiva Companies in the market include – Ipsen, Regeneron Pharmaceutical, Biocryst,, and others.

The Fibrodysplasia Ossificans Progressiva market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Fibrodysplasia Ossificans Progressiva pipeline products will significantly revolutionize the Fibrodysplasia Ossificans Progressiva market dynamics.

DelveInsight’s “Fibrodysplasia Ossificans Progressiva Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Fibrodysplasia Ossificans Progressiva, historical and forecasted epidemiology as well as the Fibrodysplasia Ossificans Progressiva market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Fibrodysplasia Ossificans Progressiva market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the Fibrodysplasia Ossificans Progressiva market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Fibrodysplasia Ossificans Progressiva Market Forecast

Some of the key facts of the Fibrodysplasia Ossificans Progressiva Market Report:

The Fibrodysplasia Ossificans Progressiva market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
In January 2025, āshibio, a privately held, clinical-stage biotechnology company developing innovative therapeutics for severe bone and connective tissue disorders, announced today that the first participant has been dosed in its ANDECAL study. This Phase 2/3 clinical trial is assessing the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of andecaliximab in patients with fibrodysplasia ossificans progressiva (FOP). The dosing of andecaliximab, āshibio’s lead product candidate, represents a significant milestone in the company’s first clinical trial targeting conditions associated with heterotopic ossification (HO), a pathological process that leads to abnormal bone formation in soft tissues like muscles, tendons, and ligaments.
According to NORD, Fibrodysplasia ossificans progressiva (FOP) is a very rare genetic connective tissue disorder characterized by the abnormal development of bone in areas of the body where bone is not normally present (heterotopic ossification), such as the ligaments, tendons, and skeletal muscles
Among the 7MM, the United States is likely to dominate the Fibrodysplasia Ossificans Progressiva treatment market due to the suitable healthcare infrastructure
According to a study by Moira et al., the prevalence of Fibrodysplasia Ossificans Progressiva is approximately 0.65 per million in North America, 0.47 per million in Western Europe, and 0.27 per million in Latin America to 0.05 per million in Africa and nearly 0.04 per million in the Asia-Pacific region.
Key Fibrodysplasia Ossificans Progressiva Companies: Ipsen, Regeneron Pharmaceutical, Biocryst,, and others
Key Fibrodysplasia Ossificans Progressiva Therapies: Palovarotene, Garetosmab, BCX9250, and others
The Fibrodysplasia Ossificans Progressiva epidemiology based on gender analyzed that females are more prevalent for Fibrodysplasia Ossificans Progressiva rather than males. It has been found that 54% females and 46% males are affected with Fibrodysplasia Ossificans Progressiva

Fibrodysplasia Ossificans Progressiva Overview

Fibrodysplasia ossificans progressiva (FOP) is a very rare genetic connective tissue disorder characterized by the abnormal development of bone in areas of the body where bone is not normally present (heterotopic ossification), such as the ligaments, tendons, and skeletal muscles. Specifically, this disorder causes the body’s skeletal muscles and soft connective tissues to undergo a metamorphosis, essentially a transformation into bone, progressively locking joints in place and making movement difficult or impossible.

Get a Free sample for the Fibrodysplasia Ossificans Progressiva Market Report:

https://www.delveinsight.com/report-store/fibrodysplasia-ossificans-progressiva-fop-market

Fibrodysplasia Ossificans Progressiva Epidemiology

Fibrodysplasia Ossificans Progressiva Epidemiology Segmentation:

The Fibrodysplasia Ossificans Progressiva market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Total Prevalence of Fibrodysplasia Ossificans Progressiva
Prevalent Cases of Fibrodysplasia Ossificans Progressiva by severity
Gender-specific Prevalence of Fibrodysplasia Ossificans Progressiva
Diagnosed Cases of Episodic and Chronic Fibrodysplasia Ossificans Progressiva

Download the report to understand which factors are driving Fibrodysplasia Ossificans Progressiva epidemiology trends @ Fibrodysplasia Ossificans Progressiva Epidemiological Insights

Fibrodysplasia Ossificans Progressiva Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Fibrodysplasia Ossificans Progressiva market or expected to get launched during the study period. The analysis covers Fibrodysplasia Ossificans Progressiva market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on

market share. The report also covers the Fibrodysplasia Ossificans Progressiva Pipeline

Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Fibrodysplasia Ossificans Progressiva Therapies and Key Companies

Palovarotene: Ipsen
Garetosmab: Regeneron Pharmaceutical
Biocryst: BCX9250

To know more about Fibrodysplasia Ossificans Progressiva treatment, visit @ Fibrodysplasia Ossificans Progressiva Medications

Fibrodysplasia Ossificans Progressiva Market Drivers

Increased Awareness and Diagnosis
Rising Research and Development
Emerging Therapies
Strong Patient Advocacy
Supportive Regulatory Environment
Potential for Rare Disease Market Growth

Fibrodysplasia Ossificans Progressiva Market Barriers

Limited Treatment Options
High Cost of Treatments
Small Patient Population
Complexity in Drug Development
Long Development Timelines

Scope of the Fibrodysplasia Ossificans Progressiva Market Repor

Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Fibrodysplasia Ossificans Progressiva Companies: Ipsen, Regeneron Pharmaceutical, Biocryst, and others
Key Fibrodysplasia Ossificans Progressiva Therapies: Palovarotene, Garetosmab, BCX9250, and others
Fibrodysplasia Ossificans Progressiva Therapeutic Assessment: Fibrodysplasia Ossificans Progressiva current marketed and Fibrodysplasia Ossificans Progressiva emerging therapies
Fibrodysplasia Ossificans Progressiva Market Dynamics: Fibrodysplasia Ossificans Progressiva market drivers and Fibrodysplasia Ossificans Progressiva market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Fibrodysplasia Ossificans Progressiva Unmet Needs, KOL’s views, Analyst’s views, FibrodysplasiaOssificans Progressiva Market Access and Reimbursement

Discover more about therapies set to grab major Fibrodysplasia Ossificans Progressiva market share @ Fibrodysplasia Ossificans Progressiva Treatment Landscape

Table of Contents

1. Fibrodysplasia Ossificans Progressiva Market Report Introduction

2. Executive Summary for Fibrodysplasia Ossificans Progressiva

3. SWOT analysis of Fibrodysplasia Ossificans Progressiva

4. Fibrodysplasia Ossificans Progressiva Patient Share (%) Overview at a Glance

5. Fibrodysplasia Ossificans Progressiva Market Overview at a Glance

6. Fibrodysplasia Ossificans Progressiva Disease Background and Overview

7. Fibrodysplasia Ossificans Progressiva Epidemiology and Patient Population

8. Country-Specific Patient Population of Fibrodysplasia Ossificans Progressiva

9. Fibrodysplasia Ossificans Progressiva Current Treatment and Medical Practices

10. Fibrodysplasia Ossificans Progressiva Unmet Needs

11. Fibrodysplasia Ossificans Progressiva Emerging Therapies

12. Fibrodysplasia Ossificans Progressiva Market Outlook

13. Country-Wise Fibrodysplasia Ossificans Progressiva Market Analysis (2019–2032)

14. Fibrodysplasia Ossificans Progressiva Market Access and Reimbursement of Therapies

15. Fibrodysplasia Ossificans Progressiva Market Drivers

16. Fibrodysplasia Ossificans Progressiva Market Barriers

17. Fibrodysplasia Ossificans Progressiva Appendix

18. Fibrodysplasia Ossificans Progressiva Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach. Media Contact

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Fibrodysplasia Ossificans Progressiva Market Set to Grow Substantially Through 2032, DelveInsight Projects | Ipsen, Regeneron Pharmaceutical, Biocryst

Nasdaq Uplisting and $20 Million Capital Raise: HNO International, Inc. (Stock Symbol: HNOI) Poised for Expansion

Investing in the Future of Clean Hydrogen Energy

HNO International, Inc. (Stock Symbol: HNOI) is at the forefront of green hydrogen innovation, developing and commercializing advanced hydrogen-based energy technologies. With a strong foundation built over 13 years, HNOI is committed to accelerating the global transition toward sustainable energy solutions. The company is making significant strides with its flagship technologies: the Scalable Hydrogen Energy Platform (SHEP™) and the Compact Hydrogen Refueling Station (CHRS™), positioning itself as a leader in the burgeoning hydrogen economy.

NASDAQ Uplist and Capital Raise with a Leading Investment Banking Firm

HNOI recently announced a major milestone—its plans to uplist to the NASDAQ and secure up to $20 million in capital through a partnership with a respected Wall Street investment banking firm. This initiative is designed to fuel the company’s expansion strategy, fund capital expenditures, and drive future acquisitions via a Regulation A offering.

The investment banking firm, which has a long-standing track record in IPOs, private placements, and SPAC transactions, sees HNOI as a key player in the global energy transition. Their Managing Director commented:

“The global demand for energy continues to climb at extraordinary rates, prompting the need for additional sources, of which HNO International is set to play a key role.”

This strategic move is expected to propel HNOI from the OTC market to a global stage, enhancing its visibility and access to institutional investors.

Major Share Reduction: Strengthening Shareholder Value

HNOI has also executed a significant share structure reduction, enhancing shareholder value and reinforcing confidence in its long-term vision. The company reduced its outstanding common stock by 82%, bringing the total outstanding shares down to only 74 million. This reduction was facilitated through a return exchange of 360 million shares by Chairman & CEO Donald Owens, reflecting strong leadership commitment to sustainable shareholder growth.

Strategic Industry Alliances: Partnerships with Global Leaders

HNOI is leveraging key partnerships to accelerate its impact across multiple industries. The company has aligned with Blue Origin, NASA, Amazon, Meta, and Microsoft, positioning itself among global innovators in clean energy technology. Additionally, HNOI has forged agreements with industry leaders to advance scalable hydrogen energy solutions:

Teaming Agreement with Pneumatic and Hydraulic Company (PHC): This collaboration will support the deployment of 1-10 MW electrolyzer production plants, refueling systems, and microgrid solutions. With clients like SpaceX, Blue Origin, and NASA, PHC brings decades of expertise in fluid power solutions and high-pressure hydrogen systems to support HNOI’s mission.
Partnership with Dumore Enterprises: HNOI is testing its Hydrogen Carbon Cleaner (HCC) technology and hydrogen-diesel blending solutions in real-world applications. This initiative is expected to demonstrate fuel efficiency improvements, emissions reductions, and maintenance cost savings, paving the way for commercial adoption across industrial and transportation sectors.

Vision for the Hydrogen Economy: CEO Shares Insights from NASDAQ Marketsite

HNOI Chairman & CEO Donald Owens recently shared his ambitious vision for the hydrogen economy in an exclusive video interview from the NASDAQ Marketsite in Times Square. Key topics discussed include:

Local Production & Consumption with SHEP™: Enabling decentralized hydrogen production to enhance energy security and reduce transportation costs.
Hydrogen Refueling & Dispensing with CHRS™: Streamlining hydrogen infrastructure for rapid adoption.
Powering Data Centers & Cryptocurrency Mining: Leveraging hydrogen to power critical infrastructure with zero-emission solutions.

Why Investors Should Pay Attention

HNOI represents a compelling investment opportunity at the intersection of renewable energy, hydrogen technology, and industrial innovation. With its upcoming NASDAQ uplist, reduced outstanding shares, and strategic partnerships with industry leaders, the company is poised for significant growth.

Investors looking to capitalize on the future of hydrogen energy should keep HNOI on their radar. The combination of cutting-edge technology, market demand for clean energy solutions, and strategic financial positioning makes this an attractive proposition in the rapidly evolving energy sector.

For more information, visit: www.hnointernational.com

DISCLAIMER: https://corporateads.com/disclaimer/

Disclosure listed on the CorporateAds website

Media Contact
Company Name: HNO International, Inc. (OTC: HNOI)
Contact Person: Donald Owens, Chairman
Email: Send Email
Phone: (951) 305-8872
Address:4115 Eastman Drive Suite B
City: Murrieta
State: California
Country: United States
Website: www.hnointernational.com

Softlogic Life Introduces Flying Santa to Sri Lanka Using Drone Technology

Santa’s sleigh in action using drone technology

In a dazzling display of creativity and innovation, Softlogic Life, Sri Lanka’s leading life insurer with the largest customer base, illuminated Colombo’s night sky at Galle Face Green with a festive spectacle like never before. For the first time in Sri Lanka, Santa Claus was seen flying in a sleigh against the starry Colombo sky, mesmerizing children and adults alike. This extraordinary moment, brought to life using cutting-edge drone technology, showcased Softlogic Life’s unwavering commitment to delivering on its promises in ways that are innovative, creative, and unprecedented.

Softlogic Life partnered with the country’s leading drone operator, ‘Drone Mudiyanse,’ and New Media Solutions to bring this dream to reality. Utilizing two state-of-the-art drones, the company flew a 12ft long Santa sleigh alongside its brand messaging over Galle Face Green, spreading hope, joy, inspiration and Christmas cheer to a delighted crowd. Social media lit up with photos and videos of the flying sleigh, as attendees shared their excitement and awe, spreading the festive cheer nationwide. The initiative’s success highlighted how technology, when paired with a clear commitment to delivering a promise, can create unforgettable and inspiring experiences.

“At Softlogic Life, we have always been committed to delivering on our promises—and we often turn to technology to achieve that in ways that are bold, innovative, and never seen before,” said Chamindri Pilimataluwe, Head of Marketing at Softlogic Life. “Flying Santa Claus across the Colombo sky was our way of bringing a moment of inspiration, joy, and hope closer to home for all Sri Lankans. As a trendsetter and the most innovative insurer in Sri Lanka, we believe we have a responsibility towards inspiring our communities to dream bigger and bolder and we hope that this drone-powered spectacle proved how a little bit of creativity and innovation can be used to make the impossible, possible. For us this initiative was not just a visual treat but a tangible example of showing how Softlogic Life uses technology to deliver on its promises while inspiring a nation to turn dreams into reality.”

Echoing this sentiment, Managing Director Iftikar Ahamed stated, “Our promises to our 1.5Mn customers goes beyond financial security; it is about delivering exceptional experiences that inspire trust, hope and positivity, so that every Sri Lankan can aspire to a great quality of life. Whether it’s a flying Santa sleigh using drone technology or settling an insurance claim in minutes using AI technology, we’re committed to reimagining possibilities, setting new benchmarks and delivering as promised.”

Softlogic Life’s collaboration with Drone Mudiyanse marked yet another milestone in its journey of innovation, setting a new benchmark for festive celebrations in Sri Lanka. By livening up the holiday season, the company underscored its mission to go beyond traditional boundaries, using technology to transform ideas into inspiring experiences. This one-of-a-kind event made possible through the company’s creative use of technology, reaffirmed Softlogic Life’s reputation as a trailblazer in the industry, blending imagination and innovation to deliver promises. The sight of Santa and his sleigh soaring across the night sky, inspired and fascinated large groups of onlookers both young and old who lit up social media with many more joyful thoughts and sentiments for the season.

Media Contact
Company Name: Softlogic Life
Contact Person: Upeksha Hettiarachchi
Email: Send Email
Country: Sri Lanka
Website: https://softlogiclife.lk/

CloudLex Unveils Lexee: Responsible AI Revolutionizing Personal Injury Law

The only software you need to run your personal injury practice

CloudLex launches Lexee, an AI-driven platform revolutionizing personal injury law with empathy, efficiency, and responsible AI.

CloudLex, the premier provider of personal injury legal technology in the U.S., proudly announces the launch of Lexee, an advanced AI initiative designed exclusively for personal injury law. Lexee represents a paradigm shift in legal technology, blending cutting-edge AI with the empathy and human connection critical to the practice of personal injury law.

Lexee addresses the unique and evolving needs of personal injury law, where efficiency must coexist with compassion, and complex casework demands innovative solutions. Lexee is not just a tool but an ongoing initiative to evolve alongside the dynamic demands of personal injury practice.

Committed to Responsible AI

Lexee is founded on CloudLex’s core principles of responsible AI development:

Enhancing Daily Work – Making legal tasks more engaging, enjoyable, and efficient.
Unlocking Efficiencies – Amplifying human judgment through AI support, not replacement.
Creating a Win-Win Solution – Empowering legal teams without compromising the human element.
Fostering a Human-Centered Culture – Prioritizing empathy, creativity, and passion in every legal interaction.

Evolving Capabilities of Lexee

Empathy-Driven Client Service

Lexee serves as the ideal first touchpoint for clients, ensuring no one feels like “just another case.” It recognizes when clients need quick answers and when a personal, human connection is necessary—helping attorneys maintain trust and compassion in every interaction.

Pre-Litigation Support for Claims That Need Faster Settlement

Lexee empowers the efficient handling of claims without overextending resources. It simplifies information gathering and creates cost-effective pre-litigation demand packages, enabling legal professionals to support clients who require quick settlement solutions.

Decoding Medical History and Injury Complexities

Lexee helps legal professionals navigate intricate medical histories and understand injury complexities. By organizing and interpreting medical records, it provides insights into injury implications and timelines, enabling attorneys to craft compelling case narratives and build stronger cases.

A Paradigm Shift in Legal Practice

Lexee represents a transformational shift in the way personal injury law is practiced. It is designed to work as a collaborative partner, ensuring AI complements human expertise rather than replacing it. As an ongoing learning process, Lexee evolves with every interaction, adapting to the unique demands of personal injury law.

“Personal injury law demands a balance of efficiency and empathy,” said Dev Shrotri, CEO of CloudLex. “Lexee is our commitment to not only enhancing the practice of personal injury law but also to driving a paradigm shift. This ongoing initiative ensures Lexee remains a dynamic, evolving ally that prioritizes the human connection essential to advocating for clients seeking justice.”

Join the Evolution

Attorneys can gain early access to Lexee and be part of this groundbreaking initiative by joining the waitlist at www.cloudlex.com/lexee.

About CloudLex

CloudLex is the leading cloud-based legal technology provider exclusively focused on personal injury law in the U.S. With tools designed to build, manage, and grow practices efficiently, CloudLex is dedicated to advancing the future of personal injury law.

For more information, visit www.cloudlex.com.

Media Contact
Company Name: CloudLex. Inc.
Contact Person: Michael Abdan, Esq.
Email: Send Email
Phone: 646-415-8307
Address:3 WTC, 175 Greenwich St.
City: New York
State: NY
Country: United States
Website: https://www.cloudlex.com/

Geschwindt Stabingas Ebling Family Funeral Homes Announce Merger with Lord-Bixler Funeral Home

Pottsville, PA – January 29, 2025 – Geschwindt Stabingas Ebling Family Funeral Homes & On-site Crematory, a trusted provider of funeral and cremation services in Schuylkill County, announces its merger with the Lord-Bixler Funeral Home in Pottsville. As part of this transition, the 1818 Mahantongo Street location will be rebranded as Lord Ebling Haus Funeral Home & Crematory, Inc.

This merger represents a significant milestone in continuing to provide compassionate and professional funeral services for the community. The rebranded facility will offer a full range of personalized services, including traditional funerals, cremation options, pre-planning, and memorial keepsakes, all under one unified name.

William C. Pugh, a respected funeral director in Pottsville, will serve as the Supervisor of the newly rebranded Lord Ebling Haus Funeral Home & Crematory, Inc. With extensive experience and strong ties to the local community, Mr. Pugh is committed to upholding the tradition of excellence that families have come to expect from these combined funeral homes.

Services for all religions, cultures, and customs are provided at Lord Ebling Haus Funeral Home & Crematory, Inc. Families can get together and pay tribute to their loved ones in a contemporary, friendly setting at their facilities.

For more information about services or to schedule a consultation, visit https://www.gsesfuneralhomes.com/pottsville-pa-funeral-home or follow the company on Facebook.

To commemorate this new chapter, a ribbon-cutting ceremony is scheduled for February 11th at the Pottsville location. Families and community members are invited to attend and celebrate this important milestone in local funeral services.

About Lord Ebling Haus Funeral Home & Crematory, Inc.

Lord Ebling Haus Funeral Home & Crematory, located in Pottsville, Pennsylvania, is a third-generation family-owned and operated funeral home dedicated to serving Schuylkill County with compassion and professionalism. The company provides a comprehensive range of individualized funeral and cremation services, including pre-planning, burial choices, and memorial gatherings, as part of the Geschwindt Stabingas Ebling Family Funeral Homes. The on-site crematory ensures that loved ones and families always remain under consistent and dedicated care. With a commitment to honoring traditions and supporting families of all faiths, the company provides tailored services to meet diverse needs.

Media Contact
Company Name: Lord Ebling Haus Funeral Home & Crematory
Contact Person: Andy Haus
Email: Send Email
Country: United States
Website: https://www.gsesfuneralhomes.com/pottsville-pa-funeral-home

Dr. Jeffrey Grosskopf Introduces Advanced Diagnostic Protocols in Wauwatosa to Address Spinal Ligament Injuries

Wauwatosa, WI – January 29, 2025 – Dr. Jeffrey Grosskopf, a chiropractor with over 15 years of experience, is advancing patient care in his Wauwatosa Practice, Epic Life Chiropractic, by introducing advanced diagnostic tools for spinal ligament injuries. Dr. Grosskopf’s approach targets the core issues of chronic pain using a series of precise imaging tests and techniques to detect damage to spinal ligaments.

Chronic pain is a significant issue in the United States, affecting 51.6 million adults and costing between $560 billion to $635 billion annually in healthcare expenses. Among the most frequent causes of this pain are spinal ligament injuries, which are difficult to detect with routine medical evaluations. These injuries can result from trauma such as car accidents, sports injuries, or repetitive strain.

“Spinal ligament injuries are a leading cause of chronic pain, but conventional diagnostic methods often miss them,” explained Dr. Grosskopf. “Our advanced diagnostics enable us to pinpoint ligament damage with greater accuracy, understand the full extent of the injury, and provide tailored solutions to help patients get back to living their lives.”

Dr. Grosskopf’s practice uses the following tools and techniques to go beyond standard evaluations:

Digital Motion X-rays (DMX): This imaging technology captures real-time spinal movement, highlighting areas of instability that static X-rays can miss.
Stress and Motion Studies: These tests assess how the spine moves under different conditions, revealing areas of instability caused by ligament injuries. By analyzing the spine’s functional performance, Dr. Grosskopf can pinpoint problematic regions with better precision.
Targeted Adjustments: Using the Integrator Adjusting Instrument and the Torque Release Technique (TRT), Dr. Grosskopf delivers precise, gentle spinal adjustments. These techniques are specifically designed to correct misalignments, reduce nerve pressure, and support the body’s natural ability to heal.

By incorporating these advanced diagnostic tools and targeted adjustment techniques, Dr. Grosskopf aims to provide more comprehensive care for patients dealing with unresolved chronic pain. He emphasizes identifying the root cause of discomfort, offering patients a clearer path toward recovery and improved quality of life.

“Patients often come to us frustrated after years of being told there’s nothing wrong or that their pain is untreatable,” adds Dr. Grosskopf. “Our diagnostics aim to give them the answers they’ve been searching for.”

For more information about Dr. Jeffrey Grosskopf’s services or to schedule an evaluation, please visit http://www.ChiropractorWauwatosa.com.

About Dr. Jeffrey Grosskopf

Dr. Jeffrey Grosskopf, the founder of Epic Life Chiropractic in Wauwatosa, specializes in identifying and addressing undiagnosed spinal injuries that contribute to chronic pain and disrupt overall health. A proud Wauwatosa native, the doctor leverages over 15 years of professional experience to deliver patient-centered care using advanced, chiropractic neurology techniques. His approach emphasizes restoring spinal health, improving nervous system function, and supporting long-term wellness.

Socials: @drjeffgrosskopf, @chiropractorwauwatosa

Media Contact
Company Name: Epic Life Chiropractic
Contact Person: Dr. Jeffrey Grosskopf
Email: Send Email
Phone: 414-426-9677
Country: United States
Website: http://www.ChiropractorWauwatosa.com/

Major Acquisition Introduces Game-Changing Energy and IoT Innovations, Setting the Stage for Long-Term Shareholder Value: Safe & Green Holdings Corp., (Stock Symbol: SGBX)

Development, Design and Fabrication of Modular Structures, Meeting the Demand for Safe and Green Solutions Across Various Industries.

Supports Third-Party and In-House Developers, Architects, Builders and Owners for Faster Execution, Greener Construction and Buildings of Higher Value.

Signed LOI for Transformative 100% Acquisition of Olenox and Machfu.com

Olenox’s Operations Include Three Vertically Integrated Business Units: Oil & Gas Production, Energy Services and Energy Technologies.

With Over 20,000 Gateways Deployed Globally, Machfu Delivers Real-Time Data Analytics, Predictive Maintenance and Operational Efficiency to Industrial Clients.

Michael McLaren, Recently Appointed CEO of SGBX as well as Founder and CEO of Olenox, to Assume Additional Role as Chairman of SGBX.

$1,274,752 Awarded by Favorable Legal Judgment, Delivering Substantial Value to Shareholders.

Safe & Green Holdings Corp., (Nasdaq: SGBX) a leading modular solutions company, operates under core capabilities which include the development, design, and fabrication of modular structures, meeting the demand for safe and green solutions across various intries. SGBX supports third-party and in-house developers, architects, builders, and owners in achieving faster execution, greener construction, and buildings of higher value.

LOI for Transformative Acquisition of Olenox and Machfu.com

On January 14th SGBX announced a binding Letter of Intent (“LOI”) to acquire 100% of the outstanding securities of New Asia Holdings Inc. (OTCQB: NAHD). The acquisition includes a diversified energy company Olenox Corp., a wholly owned subsidiary of NAHD. The SGBX acquisition also includes Machfu.com, a wholly owned subsidiary of Olenox, specializing in secure connectivity and automation solutions for industries such as oil & gas, utilities, and manufacturing.

Olenox’s operations include three vertically integrated business units: Oil & Gas Production, Energy Services, and Energy Technologies. Olenox specializes in acquiring and revitalizing underdeveloped energy assets, leveraging proprietary technologies and operational expertise to enhance production efficiency, lower costs, and minimize environmental impact.

Key achievements of Olenox include expanding production from 113 barrels of oil equivalent per day (BOE/day) to a projected 700 BOE/day through increased operational capacity and innovative technologies. By focusing on distressed and neglected oil and gas fields in Texas, Oklahoma, and Kansas, Olenox has created a scalable model that addresses industry inefficiencies while maintaining a strong commitment to sustainability. Following the acquisition of NAHD, SGBX will continue to maintain its current operations and fabrication of modular structures. In addition, the Company plans to leverage its existing facilities, including its Waldron facility in Durant, Oklahoma, to support its new operations in the oil and gas industry. SGBX management expects that this dual focus will enable the combined entity to achieve greater efficiencies and benefit from economies of scale across its business segments. This approach aligns with the Company’s overarching vision to lead advancements in sustainable energy, food, water, and shelter as essential pillars for fostering global resilience.

Olenox’s proprietary plasma pulse and ultrasonic cleaning tools set it apart from traditional energy players. These advanced technologies allow for cost-effective recovery of oil and gas while reducing the environmental footprint, ensuring alignment with global sustainability trends. Olenox’s Energy Services division, with its customized service rigs and reclamation capabilities, enhances the value of its production assets while generating additional revenue streams through third-party contracts.

Machfu.com is a trailblazer in the Industrial IoT sector. Its flagship product, the MachGateway®, and Edge-to-Enterprise™ software enable seamless integration of legacy systems with modern IoT platforms. With over 20,000 gateways deployed globally, Machfu has proven its ability to deliver real-time data analytics, predictive maintenance, and operational efficiency to industrial clients.

Machfu’s technology supports cost reduction and productivity gains by minimizing downtime and optimizing equipment performance. For example, its Bluetooth IoT gateways connect over 125 sensors per device, enabling scalable, low-cost solutions for monitoring and control in industrial environments. These capabilities directly address the growing demand for automation and digital transformation in energy and other key industries, creating high-margin recurring revenue opportunities for the combined entity.

In connection with the transaction, Michael McLaren, recently appointed CEO of SGBX, as well as founder and CEO of Olenox, will assume the additional role of Chairman of SGBX, succeeding Paul Galvin, who will remain on the board of directors.

SGBX CEO Michael McLaren stated, “We believe that the combination of Olenox and Machfu with Safe & Green will create a powerful, diversified entity with robust growth potential in both the energy and technology sectors. Olenox provides stable and growing revenues from its oil and gas assets, complemented by the scalability of Machfu’s recurring IoT revenue streams. We believe that this synergy will position the combined company to capture significant market opportunities in renewable energy, digital transformation, and industrial automation. By maintaining Safe & Green’s current modular operations, while leveraging facilities such as our Waldron facility to support oil and gas activities, we expect to achieve greater operational efficiencies and economies of scale. For Safe & Green shareholders, this transaction represents a strategic pivot toward high-growth markets. Olenox’s proven financial performance, including strong asset utilization and innovative technologies, enhances the Company’s equity position and profitability potential. Machfu’s advanced IoT capabilities further diversify the revenue base, providing exposure to a rapidly growing global market.”

Favorable Legal Judgment, Delivering Substantial Value to Shareholders

On December 27th SGBX announced a decisive legal victory in its litigation against EDI International, PC, and PVE, LLC. The Superior Court of Los Angeles County awarded a judgment in favor of Safe & Green Holdings, granting the Company $1,274,752 in damages, with additional potential awards for interest, legal costs, and attorney’s fees.

This judgment resolves claims related to intentional interference with prospective economic relations and contractual obligations, highlighting the Company’s steadfast commitment to protecting its interests and ensuring fairness for its shareholders.

The court ruled that the defendants’ actions disrupted critical economic relationships and contractual agreements, resulting in damages to Safe & Green Holdings. SGBX is committed to ensuring that the awarded damages benefit shareholders and contribute to its mission of advancing sustainable and innovative building solutions.

For more information on $SGBX, visit https://www.safeandgreenholdings.com/

DISCLAIMER: https://corporateads.com/disclaimer/

Disclosure listed on the CorporateAds website

Media Contact
Company Name: Safe & Green Holdings Corp
Contact Person: CEO Michael McLaren, Chairman and CEO
Email: Send Email
Phone: 646-240-4235
Address:990 Biscayne Boulevard Suite 501, Office 12
City: Miami
State: Florida
Country: United States
Website: https://www.safeandgreenholdings.com/